Omega Flex (OFLX) posts weaker Q2 2026 earnings but wins CE mark for MediTrac
Rhea-AI Filing Summary
Omega Flex, Inc. reported weaker results for the periods ended June 30, 2026. For the first six months, net sales were $47.15M, down 3.5% from $48.86M in 2025, while net income fell to $4.75M from $7.72M, a 38.5% decrease. For the second quarter, net sales declined 5.8% year over year and net income was 35.6% lower than the prior-year quarter. Earnings per share for the six months were $0.47, compared with $0.77 a year earlier, on 10,094,322 weighted-average shares in both periods.
Management attributes the lower earnings mainly to higher raw material, transportation, tariff, marketing, and product enhancement costs, partially offset by lower product liability reserves. Some higher costs relate to inventory procurement and the launch of a re‑engineered TracPipe flexible gas piping fitting. The company also announced that MediTrac corrugated medical tubing obtained CE mark certification under EU MDR 2017/745 as a Class IIa medical device, supporting international expansion of its medical gas tubing business.
Positive
- MediTrac CMT received CE mark certification under EU MDR 2017/745 as a Class IIa medical device, potentially enabling broader international adoption of the company’s medical gas tubing solutions.
- The company introduced a re‑engineered TracPipe flexible gas piping fitting aimed at broader residential and commercial applications, which may enhance its competitive position in gas piping markets.
- Management states it is making targeted investments in equipment and facilities to expand capacity, improve operational efficiency, and support geographic growth across existing and new markets.
Negative
- Six‑month net income declined 38.5%, from $7.72M to $4.75M, driven by higher raw material, transportation, tariff, marketing, and product enhancement costs.
- Second‑quarter net income was 35.6% below the same period in 2025, indicating sustained earnings pressure beyond a single quarter.
- Six‑month net sales fell 3.5% to $47.15M, and second‑quarter sales were 5.8% lower year over year, reflecting softer demand amid a decline in housing starts.
Filing Explained
The company says higher raw-material and marketing costs tied to inventory procurement and the new fitting will continue while it builds targeted inventory and markets the product, although it expects those costs to normalize over time.
8-K Event Classification
Key Figures
Key Terms
Conformité Européenne (CE) mark certification regulatory
European Union Medical Device Regulation (EU MDR 2017/745) regulatory
Class IIa medical device regulatory
ISO 13485:2016-certified quality management system technical
forward-looking statements regulatory
Health Care Facilities Code NFPA 99 technical
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Omega Flex (OFLX) perform financially in the first half of 2026?
What were Omega Flex (OFLX) second‑quarter 2026 results versus 2025?
Why did Omega Flex (OFLX) earnings decline in 2026?
What regulatory milestone did Omega Flex (OFLX) achieve for MediTrac?
How widely is Omega Flex’s MediTrac CMT deployed geographically?
What new product did Omega Flex (OFLX) launch in 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Not applicable
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 12, 2026, Omega Flex, Inc. (the “Company”) issued a press release reporting its results for the six months and three months ended June 30, 2026 and announcing CE Mark approval for MediTrac® corrugated medical tubing. A copy of the earnings release issued by the Company with respect to these matters is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information set forth and incorporated by reference in this Item 2.02 is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and the Company does not incorporate it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits:
| Exhibit Number |
Description | |
| 99.1 | Press Release dated August 12, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
OMEGA FLEX, INC.
| Date: August 12, 2026 | By: | /s/ Dean W. Rivest |
| Dean W. Rivest | ||
| Chief Executive Officer |
Exhibit 99.1
Manufacturer of flexible metal hose and gas piping products
| Exton, Pennsylvania | Contact: Dean W. Rivest |
| August
|
(610) 524-7272 |
PRESS RELEASE
“Omega Flex, Inc. Announces Second Quarter 2026 Earnings and
CE Mark Approval for MediTrac Corrugated Medical Tubing”
OMEGA FLEX, INC. (OFLX)
| Six Months Ended June 30, | Three Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net Sales | $ | 47,150,000 | $ | 48,855,000 | $ | 24,057,000 | $ | 25,525,000 | ||||||||
| Net Income attributable to Omega Flex, Inc. | $ | 4,752,000 | $ | 7,724,000 | $ | 2,675,000 | $ | 4,156,000 | ||||||||
| Earnings Per Share – Basic and Diluted | $ | 0.47 | $ | 0.77 | $ | 0.27 | $ | 0.41 | ||||||||
| Weighted Average Shares – Basic and Diluted | 10,094,322 | 10,094,322 | 10,094,322 | 10,094,322 | ||||||||||||
Dean W. Rivest, Chief Executive Officer of Omega Flex, Inc. (the “Company”), announced that net sales of the Company for the six months ended June 30, 2026 and 2025 were $47,150,000 and $48,855,000, respectively, decreasing by $1,705,000 or 3.5%. Net sales for the three months ended June 30, 2026 were 5.8% lower than net sales for the three months ended June 30, 2025. The decrease in net sales was mainly due to lower sales unit volumes as the overall market continued to be suppressed because of, among other factors, a decline in housing starts.
Net income for the six months ended June 30, 2026 was $4,752,000, compared to net income of $7,724,000 for the six months ended June 30, 2025, decreasing by $2,972,000 or 38.5% (the “Six Month Decrease”). Net income for the three months ended June 30, 2026 was 35.6% below net income for the same period in 2025 (the “Three Month Decrease”). The decrease in net income was mainly due to higher raw material costs (including inbound transportation costs and tariffs); marketing efforts; and product enhancement and certification related expenses. The higher costs and expenses described above were partly offset by lower product liability reserves and expenses.
Approximately 30% of the Six Month Decrease, and 54% of the Three Month Decrease, was due to the above-described higher raw material costs (including inbound transportation costs and tariffs) and marketing efforts that were attributable to the procurement of inventory and introduction of the new re-engineered flexible gas piping fitting described below. These higher costs will continue as the Company procures raw materials to achieve targeted inventory levels and markets the new fitting. However, the Company believes that these higher costs will be limited in duration and will normalize over time.
During the six months ended June 30, 2026, the Company continued to pursue product enhancements intended to strengthen its market position. On July 1, 2026, the Company introduced a re-engineered flexible gas piping fitting designed to support a broader range of applications across both residential and commercial construction markets. The new TracPipe® System branded fitting is designed to ease installation while enhancing overall safety and reliability. The Company believes that in the commercial sector, the fitting is particularly well suited for larger diameter systems, including sizes up to two inches, helping to address the requirements of more demanding installations. The Company continues to make targeted investments in equipment and facilities intended to expand capacity, enhance operational efficiency, and support geographic growth by improving its ability to serve customers and distribution partners across existing and new markets.
In addition, the Company is pleased to announce that its innovative medical-grade product, MediTrac® corrugated medical tubing (CMT), received Conformité Européenne (CE) mark certification under the European Union Medical Device Regulation (EU MDR 2017/745) in August of 2026, as a Class IIa medical device. Achieving EU MDR certification, a lengthy and rigorous process, demonstrates that MediTrac CMT meets applicable European standards for safety, quality, and clinical performance.
The Company is not aware of any other manufacturers of CMT. MediTrac CMT, developed exclusively by the Company, is patent protected and complies with the stringent requirements of Health Care Facilities Code NFPA 99, Canadian Standard Z7396.1 (Medical Gas Pipeline Systems), and now, EU MDR 2017/745.
MediTrac CMT is engineered for the safe and efficient distribution of medical gases in healthcare facilities, offering a flexible, durable, and installation-friendly alternative to traditional rigid copper tubing. It is manufactured by the Company’s subsidiary, Flex-Trac, Inc., in Exton, Pennsylvania. EU MDR compliance reflects the rigor of our design and manufacturing controls and is maintained under an ISO 13485:2016-certified quality management system. MediTrac CMT has been installed in healthcare facilities across 48 U.S. states, Canada, the United Kingdom, Southeast Asia, and other international markets.
“We are extremely proud to achieve CE mark certification for MediTrac CMT,” said Dean W. Rivest, Chief Executive Officer of Omega Flex, Inc. and President and Chief Executive Officer of Flex-Trac, Inc. “Combined with the ISO 13485:2016 quality management system certification, this milestone highlights our dedication to producing safe, reliable, and innovative medical gas tubing solutions for healthcare systems around the world. We believe MediTrac CMT has the potential to serve as a scalable growth platform that extends our engineering expertise into new geographic regions and markets while leveraging our established manufacturing and quality systems.”
INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s financial condition, results of operations, future performance, growth strategies, business initiatives and anticipated trends. Forward-looking statements can generally be identified by words such as “may,” “should,” “will,” “could,” “estimates,” “predicts,” “potential,” “continue,” “anticipates,” “believes,” “plans,” “expects,” “future,” “intends,” “projects,” the negative of these terms, or other comparable terminology. These forward-looking statements may include the Company’s projections, statements related to the Company’s anticipated growth strategies, descriptions of business initiatives and anticipated trends in the Company’s business. Forward-looking statements are neither historical facts nor assurances of future performance. Rather, they are based on current beliefs, expectations and assumptions regarding the Company’s business, strategies and anticipated events and trends. These statements are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict, many of which are outside of our control, and actual results could differ materially from those expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation, other than as required by law, to update or revise any forward-looking statements to reflect events or circumstances after the date hereof. Further information regarding risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements is included in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent reports and filings with the SEC, as applicable.